Literature DB >> 10985314

Virological and immunological characteristics of HIV treatment failure.

D Kaufmann1, M Muñoz, G Bleiber, S Fleury, B Lotti, R Martinez, W Pichler, P Meylan, A Telenti.   

Abstract

BACKGROUND: Resistance to antiretroviral treatment is prevalent. There is limited knowledge of the determinants of disease evolution in subjects infected with multidrug-resistant HIV (MDR-HIV).
METHODS: Infectivity, replication, chemokine receptor usage, and env, gag, protease and reverse transcriptase sequence analysis was performed for MDR-HIV isolates from 14 HIV-infected individuals and compared to wild-type HIV isolates from individuals naive to antiretroviral treatment. Expression of CD45RO/RA, Ki67 and interferon-gamma and CD4 proliferative response to various antigens was determined for individuals infected with MDR-HIV and compared to that in individuals with optimal suppression of viral replication.
RESULTS: Infectivity and replication are diminished for various MDR-HIV isolates, usually in the context of an increase in CD4 and CD4+CD45RA+ T-cell counts. However, a number of MDR-HIV isolates are associated with high in vivo viraemia and pronounced immunosuppression, and display in vitro levels of infectivity and replication comparable to those of wild-type strains. No specific genetic sequence or chemokine receptor usage predicted the fitness of an MDR isolate.
CONCLUSIONS: Despite the biological diversity of resistant viruses and the range of host responses observed, our descriptive analysis indicates that viral factors play a role in determining the degree of immune damage observed in the context of MDR-HIV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985314     DOI: 10.1097/00002030-200008180-00012

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.

Authors:  Terrence W Brann; Robin L Dewar; Min-Kan Jiang; Akram Shah; Kunio Nagashima; Julia A Metcalf; Judith Falloon; H Clifford Lane; Tomozumi Imamichi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.

Authors:  Wolfgang Resch; Neil Parkin; Terri Watkins; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Authors:  Wolfgang Resch; Rainer Ziermann; Neil Parkin; Andrea Gamarnik; Ronald Swanstrom
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Human immunodeficiency virus genotype and hypertriglyceridemia.

Authors:  Soni J Anderson; John F Bradley; Andrea Ferreira-Gonzalez; Carleton T Garrett
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

6.  Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.

Authors:  Viviana Simon; Neal Padte; Deya Murray; Jeroen Vanderhoeven; Terri Wrin; Neil Parkin; Michele Di Mascio; Martin Markowitz
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.

Authors:  Jennifer A Collins; M Gregory Thompson; Elijah Paintsil; Melisa Ricketts; Joanna Gedzior; Louis Alexander
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.

Authors:  Alexandra Trkola; Herbert Kuster; Christine Leemann; Claudia Ruprecht; Beda Joos; Amalio Telenti; Bernhard Hirschel; Rainer Weber; Sebastian Bonhoeffer; Huldrych F Günthard
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Authors:  Beda Joos; Alexandra Trkola; Marek Fischer; Herbert Kuster; Peter Rusert; Christine Leemann; Jürg Böni; Annette Oxenius; David A Price; Rodney E Phillips; Joseph K Wong; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.